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Abstract
AIM: To determine the effect of oral erythromycin on gastric
and small bowel transit time of capsule endoscopy.
METHODS: Consecutive patients who underwent capsule
endoscopy during the 16-mo study period were either
given 250 mg oral erythromycin, 1 h prior to swallowing
the capsule endoscope or nothing. The gastric and small
bowel transit time, and the small bowel image quality
were compared.
RESULTS: Twenty-four patients received oral erythromycin
whereas 14 patients were not given any prokinetic agent.
Patients who received erythromycin had a significantly lower
gastric transit time than control (16 min vs 70 min, P = 0.005),
whereas the small bowel transit time was comparable
between the two groups (227 min vs 183 min, P = 0.18).
Incomplete small bowel examination was found in three
patients of the control group and in one patient of the
erythromycin group. There was no significant difference
in the overall quality of small bowel images between the
two groups. A marked reduction in gastric transit time
was noted in two patients who had repeat capsule
endoscopy after oral erythromycin.
CONCLUSION: Use of oral erythromycin significantly
reduces the gastric transit time of capsule endoscopy.
© 2005 The WJG Press and Elsevier Inc. All rights reserved.
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The introduction of wireless capsule endoscopy, which
has made direct visualization of the small bowel possible,
has opened up a new chapter on small bowel imaging. Initial
comparative studies showed that wireless capsule endoscopy
is superior to push enteroscopy [1-4] or conventional
radiological imaging[5]. The wireless capsule endoscopy is
approved by the Food and Drug Administration of  USA
and is particularly useful for the diagnosis of obscure
gastrointestinal bleeding.
With the limited battery life, the current capsule
endoscope could take images for up to 8 h. Any delay in
gastric transit may inadvertently result in incomplete small
bowel examination. Whilst the capsule endoscope is passively
propelled by peristalsis down the intestinal lumen, it is
impossible to predict the time required for the capsule
endoscope to navigate through the stomach. Although the
use of prokinetic agents may potentially speed up the gastric
emptying time, the effect of prokinetic agents on the outcome
of  wireless capsule endoscopy remains undetermined.
Among various prokinetic agents, erythromycin, a motilin
agonist, has been used to speed up gastric emptying in
patients with gastroparesis[6-8]. Moreover, the use of
intravenous erythromycin has been shown to improve the
quality of upper gastro-intestinal endoscopy in patients with
upper gastro-intestinal bleeding, possibly via emptying of
the blood contents within the stomach [9]. Here, we
determined the effects of  oral erythromycin on the gastric
and small bowel transit time of the capsule endoscope as




Consecutive patients who underwent capsule endoscopy in
the Prince of  Wales Hospital of  Hong Kong between
December 2002 and March 2004 were included. The use
of prokinetic agents in these patients was based on the date
of the procedure. All patients who had this examination
after October 2003 received oral erythromycin (250 mg)
1 h prior to swallowing the capsule endoscope. In contrast,
patients who had capsule endoscopy before October 2003
did not receive any prokinetic agent and were used as
controls. Exclusion criteria included patients with swallowing
difficulties, previous gastric or small bowel surgery, allergic
to erythromycin, use of other prokinetic agents, and known
or suspected bowel obstruction. All patients gave informed
consent for undergoing the procedure.
A total of 38 patients had capsule endoscopy during the
16-mo study period. There were 17 males and 21 females
with a mean age of  60.3 (SD 18.1 years) years. Twenty-four
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(63%) patients were given oral erythromycin (250 mg) prior
to swallowing the capsule endoscope (erythromycin group)
whereas 14 (37%) patients did not receive any prokinetic
agent (control group). None of the patients in the
erythromycin group experienced any abdominal discomfort
or gastrointestinal upset.
The indications of capsule endoscopy were as follows:
unexplained iron deficiency anemia in 11, obscure
gastro-intestinal bleeding in 20, recurrent abdominal pain
in 6, and Crohn’s disease in 1. Ten patients had diabetes
mellitus and none of them was taking medications that
would alter the gastric or intestinal motility. There was no
significant difference in the demographic data, body build,
history of diabetes or thyroid disease, and indications of
capsule endoscopy between the two groups of patients
(Table 1).
Table 1  Baseline characteristics of patients
           Erythromycin         Control
(n = 24)          (n = 14)
Mean age±SD (yr)                  62.7±17.8        56.3±18.6
Male (%)  9 (37.5)           8 (57.1)
Mean body mass index (±SD)                  22.9±3.8        22.3±3.2
Diabetes mellitus (%)  7 (29.2)           3 (21.4)
Indication
    Iron deficiency anemia (%)  6 (25)           5 (36)
    Obscure gastro-intestinal bleeding (%)            12 (50)           8 (57)
    Recurrent abdominal pain (%)  5 (21)           1 (7)
    Crohn’s disease (%)  1 (4)           0 (0)
Capsule endoscopy
Capsule endoscopy was performed after 12 h of  fasting.
Eight aerials, which were connected to a battery-powered
portable data recorder, were attached to the chest and
abdominal wall of the patients prior to the procedure.
Patients were asked to swallow the M2A® capsule endoscope
(Given Imaging, Yoqneam, Israel) with plenty of  water
mixed with simethicone to eliminate small bubbles in the
gastrointestinal tract. No bowel cleansing agent was used.
Patients were allowed to resume clear fluid diet, 4 h after
swallowing the capsule endoscope. The sensor array and
recorder were removed from the patients after 8 h of
recording. The recorded images were then downloaded to
the workstation and viewed by the RAPID software (Given
Imaging). Patients were monitored for any abdominal
discomfort and pain during and after the examination. The
time of spontaneous passage of the capsule endoscope was
recorded. Patients who were uncertain of the natural
passage of the capsule endoscope were called back for
abdominal x-ray to check for possible retention of the
capsule endoscope.
Gastric and small bowel transit time
All capsule images were independently viewed by two
endoscopists who were unaware of the use of prokinetic
agents. Gastric transit time was defined as the time taken
from the first gastric image to the first duodenal image.
Due to the potential difficulty in accurately identifying the
ileo-cecal valve, small bowel transit time was defined as the
time taken between the first duodenal image and the first
cecal image. Cases having capsules passed to the cecum
were considered to be complete small bowel examination.
The overall quality of small bowel images was graded as
satisfactory or unsatisfactory by the viewers according to
the percentage of good and clear images that were not
obscured by food particles or bile. Satisfactory image was
defined when more than 90% of the images were optimal
and clear. All discrepant findings between the two viewers
were resolved on discussion.
Statistical analysis
Categorical data were analyzed by Pearson χ2 test whereas
numerical data were analyzed by Student’s t-test. All statistical
analyses were made by the statistical software SPSS version
11.5 (SPSS Inc., Chicago, IL, USA). A two-sided P value of
less than 0.05 was considered statistically significant.
RESULTS
Effects of erythromycin on gastric transit time
There was no retention of the capsule endoscope in these
38 examinations. The mean gastric and small intestinal transit
time in all patients was 35.9 and 218 min respectively.
Notably, the gastric transit time was significantly lower
in the erythromycin group. The mean gastric transit was
15.8 min (range <1-60 min) in the erythromycin group and
70.2 min (range 1-298 min) in the control group (P = 0.005).
While the longest gastric transit time in the erythromycin
group was 60 min, five (36%) patients in the control group
had gastric transit time of more than 1 h. On the other
hand, there was no significant difference in the gastric transit
time between diabetic and non-diabetic patients (mean 34.2
vs 36.4 min, P = 0.92). There was also no significant
association between gastric transit time and age (P = 0.88),
gender (P = 0.73), or body mass index (P = 0.22) of the
patients.
Effects of erythromycin on small bowel examination
One (4%) patient in the erythromycin group had incomplete
small bowel examination due to the prolonged small bowel
transit time of more than 7 h. In contrast, 3 (21%) patients
in the control group had incomplete small bowel examination
(P = 0.13 vs erythromycin group). The reasons were the
prolonged gastric and small bowel transit time in two and
technical failure in one. For those who had complete small
bowel examination, the small bowel transit time was
comparable in the erythromycin (mean 227 min, range
85-446 min) and control groups (183 min, range 117-401 min;
P = 0.18, Table 2). Unsatisfactory images were obtained
in 46% patients of the erythromycin group and in 36% of
patients of the control group (P = 0.74).
Effects of erythromycin on repeat capsule endoscopy
Four patients had repeat capsule endoscopy due to
incomplete or sub-optimal examination. The minimal interval
between the two examinations was 4 d. Two patients
received erythromycin only on the second examination while
the other two patients received erythromycin in both
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examinations. As shown in Figure 1, there was a marked
reduction in gastric transit time of the two patients who
were given erythromycin in the second examination. In
contrast, there was no apparent change in gastric transit
time of the two patients who were given erythromycin in both
examinations. The gastric transit time was less than 50 min in
all examinations pre-treated with oral erythromycin.
Figure 1  Changes in gastric transit time in patients undergoing repeated
capsule endoscopy. Four patients had repeat capsule endoscopy examinations.
Two patients (CSK and LMZ), as shown by the black lines, received only
erythromycin on the second examination and there was a marked reduction in
gastric transit time in the second examination after the use of oral erythromycin.
The other patients (WT and MPH), as illustrated by the dotted lines, received
erythromycin in both examinations and the gastric emptying time was less than
50 min in both examinations.
Table 2  Gastric and small bowel transit of capsule endoscopy in
two groups of patients (mean±SD)
       Erythromycin           Control  P
               (n = 24)            (n = 14)
Gastric transit time (min)              15.8±16.8          70.3±88.1       0.005
Small bowel transit time (min)              226.5±84.0        183.0±91.2      0.18
Incomplete small bowel examination (%)  1 (4)              3 (21)           0.13
Image quality (%)
    Satisfactory                  13 (54)              9 (64)           0.74
    Unsatisfactory                  11 (46)              5 (36)
DISCUSSION
As gastric and small bowel transit time shows considerable
inter-individual variations and the prime interest of the
capsule endoscopy is to examine the small bowel only, ways
to enhance gastric transit time without compromising small
bowel examination would potentially improve the outcome
of this investigation. However, the effect of prokinetic
agent on this relatively new examination remains elusive. In
this study, we specifically addressed the effect of oral
erythromycin on gastric and small bowel transit time in
patients undergoing capsule endoscopy.
Erythromycin promotes gastric emptying by binding to
motilin receptors and acts as a motilin agonist. The use of
low dose intravenous erythromycin has been shown to
improve gastric emptying in patients with diabetic
gastroparesis[7]. Moreover, erythromycin infusion prior to
endoscopy in patients with recent hematemesis has been
shown to make endoscopy easier, and reduces the need for
a repeat procedure by enhancing the emptying of blood
within the stomach[9]. Results from this study showed that
the use of low dose oral erythromycin could enhance gastric
transit time of the wireless capsule endoscopy. The gastric
transit time in the 24 patients who received erythromycin
was all within 60 min. In contrast, 5 (36%) patients in the
control group had gastric transit time of more than 1 h. In
a previous volunteer study, it was noted that the mean
gastric transit time of capsule endoscopy is 63 min (range
10-319 min)[10]. This result is comparable to the findings in
our control group. To further support our findings, there
was a marked reduction in gastric transit time in the two
patients who used oral erythromycin on the second
examination only.
Other than speeding up the gastric transit time, the use
of erythromycin was not associated with any significant
changes in small bowel transit time. On the other hand,
patients receiving erythromycin tended to have a higher
rate of complete small bowel examination. This is probably
due to the shortened gastric transit time instead of alterations
in small bowel passage by the use of erythromycin. More
importantly, the use of erythromycin did not appear to alter
the overall quality of small bowel images. The percentage
of “unsatisfactory” small bowel images reported in this study
was relatively high, which may be related to the use of very
stringent criteria for satisfactory images, i.e., >90% clear
and optimal images. Moreover, we did not use any bowel
cleansing agent in this study, which may further improve
the quality of small bowel images[11]. It was shown in a small
uncontrolled study that the use of polyethylene glycol may
also shorten the transit time of the capsule endoscopy
through the stomach and small bowel[12]. It remains to be
determined whether the combined use of  prokinetic agents
and bowel cleansing agent has synergistic effect on small
bowel transit time.
Erythromycin is a safe and cheap antibiotic, which can
be conveniently given via oral route. It is also relatively free
of adverse reactions including drug sensitivity. Although
most published data used an intravenous preparation of
erythromycin, we found that the use of oral dosage was
also effective for this purpose. Apart from erythromycin,
there are several other prokinetic agents that may be used
in reducing gastric transit time during capsule endoscopy.
Cisapride, which was previously used as a gastric prokinetic
agent, is associated with fatal arrhythmia in susceptible
individuals[13,14] and has been withdrawn by the Food
and Drug Administration in 1999[15]. Domperidone and
metoclopramide are also used in treating symptomatic
patients with gastroparesis. However, the latter is not
infrequently associated with extra-pyramidal side effects.
Recently, the 5-HT4 receptor partial agonist, tegaserod, is
found to accelerate gastric emptying and gastro-intestinal
transit time in healthy male subjects[16]. Whether these drugs
can also be used as prokinetic agents for capsule endoscopy
remains to be determined and it is interesting to compare
the effects of different prokinetic agents in future studies.
Although this was a non-randomized study, most of the
potential confounding factors were comparable in the two
groups. All demographic and clinical details of the two
groups were matched. Moreover, all viewers were blinded































gastric transit time, it is not difficult to anticipate that the
time spent by the examiners on reviewing the images would
be reduced accordingly. This may be another advantage of
using prokinetic agents in this rather time-consuming
examination.
In summary, erythromycin given orally prior to
swallowing capsule endoscope significantly reduces the gastric
emptying time without compromising small bowel transit
time and image quality. Further randomized study is
necessary to evaluate the role of various prokinetic agents
in the performance of  capsule endoscopy.
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